-+ 0.00%
-+ 0.00%
-+ 0.00%

Reported Sunday, Benitec Biopharma Reports Sustained Disease-Modifying Outcomes And Durable Responses In BB-301 Phase 1b/2a OPMD Clinical Study

Benzinga·01/12/2026 08:23:47
Listen to the news
  •  Patient 1 of Cohort 1 has now completed the 24-month follow-up timepoint, and at month-24 post-treatment Patient 1 continued to demonstrate the powerful disease-modifying effects of BB-301, with deepening improvements in post-swallow residue and total dysphagic symptom burden as compared to the 12-month follow-up timepoint
  • Patient 4 of Cohort 1 continued to experience strong response to BB-301 at the 12-month follow-up timepoint
  • The first 4 patients enrolled into Cohort 1 have completed the 12-month statistical follow-up period, and all 4 Completers were formal Responders to BB-301 at the month-12 follow-up timepoint demonstrating durable response to BB-301